NCT07010471: A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine
- State
- Under way
- Phase
- Phase 3
- People
- 160 planned
- Started
- 9 Jul 2025
- Primary completion
- Dec 2026
- Arms
- Part A: Double-Blind Treatment Period, Part B: Open-Label Extension Treatment Period
- Results
- None posted
- 8 Jun 2025: Trial registered
- 9 Jul 2025: Trial started